IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance | Citedby Results | Cancer Research Communications | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

Cancer Research Communications (2023) 3 (4): 576–591.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

SBL-JP-0004: A promising dual inhibitor of JAK2 and PI3KCD against gastric cancer

HASSAN M. OTIFI

Oncology Research (2025) 33 (1): 235.

Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents

Filippo Spriano
Chiara Tarantelli
Luciano Cascione
Eugenio Gaudio
Gaetanina Golino
Lorenzo Scalise
Maria Teresa Cacciapuoti
Emanuele Zucca
Anastasios Stathis
Patrick H. Van Berkel
Giorgio Inghirami
Francesca Zammarchi
Francesco Bertoni

British Journal of Haematology (2024) 205 (5): 1873.

Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy

Chiara Tarantelli
David Wald
Nicolas Munz
Filippo Spriano
Alessio Bruscaggin
Eleonora Cannas
Luciano Cascione
Eugenio Gaudio
Alberto J. Arribas
Shivaprasad Manjappa
Gaetanina Golino
Lorenzo Scalise
Maria Teresa Cacciapuoti
Emanuele Zucca
Anastasios Stathis
Giorgio Inghirami
Patrick H. Van Berkel
Davide Rossi
Paolo F. Caimi
Francesca Zammarchi
Francesco Bertoni

Haematologica (2024) 109 (10): 3314.

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Alberto J. Arribas
Sara Napoli
Eugenio Gaudio
Charles Herbaux
Eleonora Cannas
Chiara Tarantelli
Roberta Bordone-Pittau
Luciano Cascione
Nicolas Munz
Luca Aresu
Jacopo Sgrignani
Andrea Rinaldi
Ivo Kwee
Davide Rossi
Andrea Cavalli
Emanuele Zucca
Georg Stussi
Anastasios Stathis
Callum Sloss
Matthew S. Davids
Francesco Bertoni

Blood Advances (2024) 8 (24): 6268.

A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy

Mathias Wenes
Anouk Lepez
Vladimir Arinkin
Kinsey Maundrell
Orsolya Barabas
Federico Simonetta
Valérie Dutoit
Pedro Romero
Jean-Claude Martinou
Denis Migliorini

Molecular Therapy: Oncology (2024) 32 (4): 200897.

Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers

Pavlina Spiliopoulou
Paramjit Kaur
Tracey Hammett
Giusy Di Conza
Michael Lahn

Cancer Drug Resistance (2024)

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib

Lars van der Veen
Michael Schmitt
Marcel A. Deken
Michael Lahn

International Journal of Toxicology (2023) 42 (6): 515.

Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles

Virender Kumar
Ram I. Mahato

Cancer Letters (2023) 579: 216462.